

<b>FORM D</b>
Notice of Exempt Offering of Securities

**UNITED STATES SECURITIES  
AND EXCHANGE COMMISSION  
Washington, D.C.**

<b>OMB APPROVAL</b>
OMB Number: 3235-0076
Expires: August 31, 2015
Estimated Average burden hours per response: 4.0

**1. Issuer's Identity**

CIK (Filer ID Number) <b>0000318306</b>	Previous Name(s) <input type="checkbox"/> None <b>CHEMEX PHARMACEUTICALS INC</b> <b>CHEMEX CORP/WY</b>	Entity Type <input checked="" type="radio"/> Corporation <input type="radio"/> Limited Partnership <input type="radio"/> Limited Liability Company <input type="radio"/> General Partnership <input type="radio"/> Business Trust <input type="radio"/> Other
Name of Issuer <b>ACCESS PHARMACEUTICALS INC</b>		
Jurisdiction of Incorporation/Organization <b>DELAWARE</b>		
Year of Incorporation/Organization <input checked="" type="radio"/> Over Five Years Ago <input type="radio"/> Within Last Five Years (Specify Year) <input type="text"/> <input type="radio"/> Yet to Be Formed		

**2. Principal Place of Business and Contact Information**

Name of Issuer <b>ACCESS PHARMACEUTICALS INC</b>			
Street Address 1 <b>2600 STEMMONS FREEWAY</b>		Street Address 2 <b>SUITE 176</b>	
City <b>DALLAS</b>	State/Province/Country <b>TEXAS</b>	ZIP/Postal Code <b>75207</b>	Phone No. of Issuer <b>214-905-5100</b>

**3. Related Persons**

Last Name <b>Thompson</b>	First Name <b>Stephen</b>	Middle Name <b>B.</b>	
Street Address 1 <b>2600 Steemons Freeway</b>		Street Address 2 <b>Suite 176</b>	
City <b>Dallas</b>	State/Province/Country <b>TEXAS</b>	ZIP/Postal Code <b>75207</b>	
Relationship:	<input checked="" type="checkbox"/> Executive Officer	<input type="checkbox"/> Director	<input checked="" type="checkbox"/> Promoter

Clarification of Response (if Necessary)

Last Name <b>Davis</b>	First Name <b>Jeffrey</b>	Middle Name <b>B.</b>
Street Address 1 <b>2600 Stemmons Freeway</b>		Street Address 2 <b>Suite 176</b>
City	State/Province/Country	ZIP/Postal Code

Dallas TEXAS 75207

Relationship:  Executive Officer  Director  Promoter

Clarification of Response (if Necessary)

---

Last Name First Name Middle Name  
Rouhandeh Steven H.

Street Address 1 Street Address 2  
2600 Stemmons Freeway Suite 176

City State/Province/Country ZIP/Postal Code  
Dallas TEXAS 75207

Relationship:  Executive Officer  Director  Promoter

Clarification of Response (if Necessary)

---

Last Name First Name Middle Name  
Ahn, Ph.D. Mark J.

Street Address 1 Street Address 2  
2600 Stemmons Freeway Suite 176

City State/Province/Country ZIP/Postal Code  
Dallas TEXAS 75207

Relationship:  Executive Officer  Director  Promoter

Clarification of Response (if Necessary)

---

Last Name First Name Middle Name  
Alvino Mark J.

Street Address 1 Street Address 2  
2600 Stemmons Freeway Suite 176

City State/Province/Country ZIP/Postal Code  
Dallas TEXAS 75207

Relationship:  Executive Officer  Director  Promoter

Clarification of Response (if Necessary)

---

Last Name First Name Middle Name  
Howell, M.D. Stephen B.

Street Address 1 Street Address 2  
2600 Stemmons Freeway Suite 176

City State/Province/Country ZIP/Postal Code  
Dallas TEXAS 75207

Relationship:  Executive Officer  Director  Promoter

Clarification of Response (if Necessary)

#### 4. Industry Group

- Agriculture
- Banking & Financial Services
  - Commercial Banking
  - Insurance
  - Investing
  - Investment Banking
  - Pooled Investment Fund
  - Other Banking & Financial Services
- Business Services
  - Energy
    - Coal Mining
    - Electric Utilities
    - Energy Conservation
    - Environmental Services
    - Oil & Gas
    - Other Energy
- Health Care
  - Biotechnology
  - Health Insurance
  - Hospitals & Physicians
  - Pharmaceuticals
  - Other Health Care
- Manufacturing
- Real Estate
  - Commercial
  - Construction
  - REITS & Finance
  - Residential
  - Other Real Estate
- Retailing
- Restaurants
- Technology
  - Computers
  - Telecommunications
  - Other Technology
- Travel
  - Airlines & Airports
  - Lodging & Conventions
  - Tourism & Travel Services
  - Other Travel
- Other

#### 5. Issuer Size

- | Revenue Range  | Aggregate Net Asset Value Range                    |
|--|--|
| <input type="radio"/> No Revenues                    | <input type="radio"/> No Aggregate Net Asset Value |
| <input type="radio"/> \$1 - \$1,000,000              | <input type="radio"/> \$1 - \$5,000,000            |
| <input type="radio"/> \$1,000,001 - \$5,000,000      | <input type="radio"/> \$5,000,001 - \$25,000,000   |
| <input type="radio"/> \$5,000,001 - \$25,000,000     | <input type="radio"/> \$25,000,001 - \$50,000,000  |
| <input type="radio"/> \$25,000,001 - \$100,000,000   | <input type="radio"/> \$50,000,001 - \$100,000,000 |
| <input type="radio"/> Over \$100,000,000             | <input type="radio"/> Over \$100,000,000           |
| <input checked="" type="radio"/> Decline to Disclose | <input type="radio"/> Decline to Disclose          |
| <input type="radio"/> Not Applicable                 | <input type="radio"/> Not Applicable               |

#### 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

<input type="checkbox"/>	Rule 504(b)(1) (not (i), (ii) or (iii))	<input type="checkbox"/>	Rule 505
<input type="checkbox"/>	Rule 504 (b)(1)(i)	<input type="checkbox"/>	Rule 506(b)
<input type="checkbox"/>	Rule 504 (b)(1)(ii)	<input type="checkbox"/>	Rule 506(c)
<input type="checkbox"/>	Rule 504 (b)(1)(iii)	<input type="checkbox"/>	Securities Act Section 4(a)(5)
<input type="checkbox"/>		<input type="checkbox"/>	Investment Company Act Section 3(c)

#### 7. Type of Filing

- New Notice      Date of First Sale             First Sale Yet to Occur  
 Amendment

## 8. Duration of Offering

Does the Issuer intend this offering to last more than one year?

Yes  No

## 9. Type(s) of Securities Offered (select all that apply)

- Pooled Investment Fund Interests  Equity
- Tenant-in-Common Securities  Debt
- Mineral Property Securities  Option, Warrant or Other Right to Acquire Another Security
- Security to be Acquired Upon  
 Exercise of Option, Warrant or Other Right to Acquire Security  Other (describe)

**1,000 shares of Series B Cumulative Convertible Preferred Stock and warrants to purchase 20,000,000 shares of Common Stock at an exercise price of \$0.50 per share.**

## 10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?

Yes  No

Clarification of Response (if Necessary)

## 11. Minimum Investment

Minimum investment accepted from any outside investor

\$  USD

## 12. Sales Compensation

Recipient

Recipient CRD Number

None

(Associated) Broker or Dealer

None

(Associated) Broker or Dealer CRD Number

None

Street Address 1

Street Address 2

City

State/Province/Country

ZIP/Postal Code

State(s) of Solicitation

All States

## 13. Offering and Sales Amounts

Total Offering Amount \$  USD  Indefinite

Total Amount Sold \$  USD

Total Remaining to be Sold \$  USD  Indefinite

Clarification of Response (if Necessary)

The offering consists of \$4,703,000 in cash and the conversion of approximately \$5,297,000 of outstanding dividends payable on the Issuer's Series A Preferred Stock.

## 14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,   
Number of such non-accredited investors who already have invested in the offering

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

## 15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$  USD  Estimate

Finders' Fees \$  USD  Estimate

Clarification of Response (if Necessary)

## 16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$  USD  Estimate

Clarification of Response (if Necessary)

## Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

### Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this

notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
<b>ACCESS PHARMACEUTICALS INC</b>	<b>/s/ Stephen B. Thompson</b>	<b>Stephen B. Thompson</b>	<b>Chief Financial Officer</b>	<b>2012-11-01</b>